MedTrace Logo

Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors

NCT05235607 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-02-11

No results posted yet for this study

Summary

This single center, single arm and prospective study aimed to establish gene mutation database and select the neoantigens in patients with advanced malignant melanoma, bladder cancer and colorectal cancer. Then, we intended to explore the safety and efficacy of individual tumor antigen-sensitized DC vaccine and their sensitized T cells in these solid cancers.

Conditions

Interventions

BIOLOGICAL

Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration

subcutaneous administration

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Ji-Yan Liu · Sichuan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-06-01
Completion
2023-12-02

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05235607 on ClinicalTrials.gov